Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Primary Central Nervous System Lymphoma (HOVON)
2009-014722-42Phase 3Active
- Sponsor
- HOVON
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in primary central nervous system lymphoma (PCNSL) and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by HOVON. Primary endpoint: Event-free survival. Started Jan 2010; status: active.
02
Drugs
rituximab
03
Conditions
primary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2009-014722-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014722-42.